Literature DB >> 12004286

Intracellular carbovir triphosphate levels in patients taking abacavir once a day.

Marianne Harris, David Back, Sean Kewn, Salima Jutha, Raymond Marina, Julio S G Montaner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12004286     DOI： 10.1097/00002030-200205240-00021

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  15 in total

Review 1.  Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.

Authors:  Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.

Authors:  Peter J Ruane; Andrew D Luber
Journal:  MedGenMed       Date:  2004-04-06

3.  Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.

Authors:  Elijah Paintsil; Ginger E Dutschman; Rong Hu; Susan P Grill; Chuan-Jen Wang; Wing Lam; Fang-Yong Li; Musie Ghebremichael; Veronika Northrup; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

Authors:  Paul D Baum; Paul M Sullam; Cheryl A Stoddart; Joseph M McCune
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

Review 5.  Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.

Authors:  Chad J Achenbach; Kimberly K Scarsi; Robert L Murphy
Journal:  Adv Ther       Date:  2010-03-05       Impact factor: 3.845

Review 6.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

7.  Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.

Authors:  Graeme Moyle; Marta Boffito; Carl Fletcher; Chris Higgs; Phillip E Hay; Ivy H Song; Yu Lou; Geoffrey J Yuen; Sherene S Min; Elena M Guerini
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Abacavir/lamivudine combination in the treatment of HIV: a review.

Authors:  Geetha Sivasubramanian; Emmanuel Frempong-Manso; Rodger D Macarthur
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

9.  Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Authors:  Alain Pruvost; Eugènia Negredo; Frédéric Théodoro; Jordi Puig; Mikaël Levi; Rafaela Ayen; Jacques Grassi; Bonaventura Clotet
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 10.  A review of the pharmacokinetics of abacavir.

Authors:  Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.